NASDAQ OMX

New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria

Dela

Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options

CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.

Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed  illumi gene® Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal. 

" illumi gene Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria," said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. "Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions.  illumi gene Malaria shows this capacity."

illumi gene Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.

Despite a 60% decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world's population is at risk of malaria (2). In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths (3). Also that year, Sub-Saharan Africa was home to 90% of malaria cases and 92% of malaria deaths (4). More than two-thirds (70%) of all malaria deaths occur in children under the age of five (5).

While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as "loads." Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.

"People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging," said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. "If testing doesn't identify them, eliminating malaria is impossible because these individuals can spread the disease to others."

That scenario is playing out in the fact that malaria is no longer only a disease of sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14% to 86% in more recent studies. On pooling the reports, nearly 43% of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70% of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries. 

While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of  illumi gene Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat.  illumi gene Malaria is user-friendly, doesn't require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.

"This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread," said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.

The availability of the field laboratory-deployable and user-friendly,  illumi gene Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.

"Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it," said Kraeutler. 

illumi gene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company's global distribution network. It is the tenth assay now available on our  illumi gene platform that is in use in nearly 1,500 institutions around the world.

1 - Meridian news release, "New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis", 1.26.16
2 - World Health Organization: 10 facts on malaria (http://www.who.int/features/factfiles/malaria/en/) Updated December 2016
3 - ibid
4 - ibid
5 - ibid
6 - The World Health Organization, Global Technical Strategy for Malaria: 2016-2030

About  Meridian Bioscience illumigene Malaria & LAMP Technology

  • illumi gene Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite.
  • LAMP (Loop Mediated Isothermal Amplification) is Molecular detection technology which targets DNA and uses premeasured and self-contained reagents.  Unlike current PCR testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results.  illumi gene testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
  • illumi gene technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to perform the test. Results are available in under an hour.
  • LAMP-based  illumi gene tests are already used to diagnose infectious diseases including C. difficile, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
  • illumi gene tests have been approved and used in other diseases for over 5 years.
  • The benefits of  illumi gene Malaria are highlighted on the microsite: www.molecularendsmalaria.com.

About Meridian Bioscience, Inc 
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

For Investor Relations, contact:     
513-271-3700
John A. Kraeutler, Chief Executive Officer

For all other inquiries, contact:
513-403-7222
Joe Shields




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme

OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00Pressmeddelande

Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and  Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t

CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00Pressmeddelande

SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856  Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1

Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31Pressmeddelande

NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999.  "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man

CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00Pressmeddelande

CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i

HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18Pressmeddelande

HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys.   -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum